Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 485687, 8 pages
http://dx.doi.org/10.1155/2014/485687
Research Article

Association of Fibrinogen with Severity of Stable Coronary Artery Disease in Patients with Type 2 Diabetic Mellitus

1Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China
2Department of Cardiology, The Fifth Hospital of Wuhan & Affiliated Guangci Hospital of Wuhan University, Wuhan 430050, China

Received 26 January 2014; Revised 4 March 2014; Accepted 4 March 2014; Published 6 April 2014

Academic Editor: Stamatios Theocharis

Copyright © 2014 Li-Feng Hong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Ndrepepa, S. Braun, L. King et al., “Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease,” American Journal of Cardiology, vol. 111, no. 6, pp. 804–810, 2013. View at Google Scholar
  2. G. De Luca, M. Verdoia, E. Cassetti et al., “High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population,” Journal of Thrombosis and Thrombolysis, vol. 31, no. 4, pp. 458–463, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. R. D. McBane II, R. M. Hardison, and B. E. Sobel, “Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with tyype 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial),” American Journal of Cardiology, vol. 105, no. 1, pp. 17–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. G. P. Devendra, S. A. Hart, E. J. Whitney, and R. A. Krasuski, “Impact of fibrinogen levels on angiographic progression and 12-year survival in the armed forces regression study,” Angiology, vol. 61, no. 4, pp. 333–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Bickel, H. J. Rupprecht, S. Blankenberg et al., “Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease,” American Journal of Cardiology, vol. 89, no. 8, pp. 901–908, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Danesh, S. Lewington, S. G. Thompson et al., “Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis,” Journal of the American Medical Association, vol. 294, no. 14, pp. 1799–1809, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Shojaie, M. Pourahmad, A. Eshraghian, H. R. Izadi, and F. Naghshvar, “Fibrinogen as a risk factor for premature myocardial infarction in Iranian patients: a case control study,” Vascular Health and Risk Management, vol. 5, pp. 673–676, 2009. View at Google Scholar · View at Scopus
  8. D. Green, N. Foiles, C. Chan, P. J. Schreiner, and K. Liu, “Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study,” Atherosclerosis, vol. 202, no. 2, pp. 623–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. I. I. Ragino, V. A. Baum, I. V. Polonskaia, S. R. Baum, and I. P. Nikitin, “Oxidized fibrinogen and its relationship with hemostasis disturbances and endothelial dysfunction during coronary heart disease and myocardial infarction,” Kardiologiia, vol. 49, no. 9, pp. 4–8, 2009. View at Google Scholar · View at Scopus
  10. C. S. Park, S.-H. Ihm, K.-D. Yoo et al., “Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA,” American Journal of Cardiology, vol. 105, no. 9, pp. 1284–1288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Rogowski, I. Shapira, H. Peretz, and S. Berliner, “Glycohaemoglobin as a determinant of increased fibrinogen concentrations and low-grade inflammation in apparently healthy nondiabetic individuals,” Clinical Endocrinology, vol. 68, no. 2, pp. 182–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Madden, G. Lee, D. P. Kotler et al., “Association of antiretroviral therapy with fibrinogen levels in HIV-infection,” AIDS, vol. 22, no. 6, pp. 707–715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Toss, J. Gnarpe, H. Gnarpe, A. Siegbahn, B. Lindahl, and L. Wallentin, “Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease,” European Heart Journal, vol. 19, no. 4, pp. 570–577, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. T. C. Rodrigues, J. K. Snell-Bergeon, D. M. Maahs, G. L. Kinney, and M. Rewers, “Higher fibrinogen levels predict progression of coronary artery calcification in adults with type 1 diabetes,” Atherosclerosis, vol. 210, no. 2, pp. 671–673, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Green, C. Chan, J. Kang et al., “Longitudinal assessment of fibrinogen in relation to subclinical cardiovascular disease: the CARDIA study,” Journal of Thrombosis and Haemostasis, vol. 8, no. 3, pp. 489–495, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Ang, K. B. Thani, M. Ilapakurti, M. S. Lee, V. Palakodeti, and E. Mahmud, “Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention,” Journal of the American College of Cardiology, vol. 61, no. 1, pp. 23–34, 2013. View at Google Scholar
  17. R. Von Känel, J. F. Thayer, and J. E. Fischer, “Nighttime vagal cardiac control and plasma fibrinogen levels in a population of working men and women,” Annals of Noninvasive Electrocardiology, vol. 14, no. 2, pp. 176–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Von Känel, S. Bellingrath, and B. M. Kudielka, “Association between longitudinal changes in depressive symptoms and plasma fibrinogen levels in school teachers,” Psychophysiology, vol. 46, no. 3, pp. 473–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. B. M. Kudielka, S. Bellingrath, and R. von Känel, “Circulating fibrinogen but not D-dimer level is associated with vital exhaustion in school teachers,” Stress, vol. 11, no. 4, pp. 250–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Tousoulis, N. Papageorgiou, E. Androulakis, A. Briasoulis, C. Antoniades, and C. Stefanadis, “Fibrinogen and cardiovascular disease: genetics and biomarkers,” Blood Reviews, vol. 25, no. 6, pp. 239–245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. E. V. Theodoraki, T. Nikopensius, J. Suhorutšenko et al., “Fibrinogen beta variants confer protection against coronary artery disease in a Greek case-control study,” BMC Medical Genetics, vol. 11, no. 1, article 28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Chen, M. Xu, L. Jin, J. Chen, and W. Chen, “Association of β-fibrinogen gene -148C/T and -455G/A polymorphisms and coronary artery disease in Chinese population: a meta analysis,” Science in China C: Life Sciences, vol. 51, no. 9, pp. 814–820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Sun, H. Ma, D. Xu et al., “Association between -455G/A and fibrinogen in a Chinese population,” Acta Cardiologica, vol. 64, no. 3, pp. 357–361, 2009. View at Google Scholar
  24. I. Behague, O. Poirier, V. Nicaud et al., “β Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM study,” Circulation, vol. 93, no. 3, pp. 440–449, 1996. View at Google Scholar · View at Scopus
  25. D. R. Kafle and P. Shrestha, “Study of fibrinogen in patients with diabetes mellitus,” Nepal Medical College Journal, vol. 12, no. 1, pp. 34–37, 2010. View at Google Scholar · View at Scopus
  26. G. G. Gensini, “A more meaningful scoring system for determining the severity of coronary heart disease,” American Journal of Cardiology, vol. 51, no. 3, p. 606, 1983. View at Google Scholar · View at Scopus
  27. G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Núñez, E. Núñez, J. Sanchis, V. Bodí, and A. Llàcer, “Prognostic value of leukocytosis in acute coronary syndromes: the cinderella of the inflammatory markers,” Current Medicinal Chemistry, vol. 13, no. 18, pp. 2113–2118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Särndahl, I. Bergström, V. P. Brodin, J. Nijm, H. L. Setterud, and L. Jonasson, “Neutrophil activation status in stable coronary artery disease,” PLoS ONE, vol. 2, no. 10, Article ID e1056, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Madjid, I. Awan, J. T. Willerson, and S. W. Casscells, “Leukocyte count and coronary heart disease: implications for risk assessment,” Journal of the American College of Cardiology, vol. 44, no. 10, pp. 1945–1956, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. N. Zairis, E. N. Adamopoulou, S. J. Manousakis et al., “The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes,” Atherosclerosis, vol. 194, no. 2, pp. 397–402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. L. M. Biasucci, “CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper,” Circulation, vol. 110, no. 25, pp. e560–e567, 2004. View at Google Scholar · View at Scopus
  33. H. Toss, B. Lindahl, A. Siegbahn, and L. Wallentin, “Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease,” Circulation, vol. 96, no. 12, pp. 4204–4210, 1997. View at Google Scholar · View at Scopus
  34. G. Montalescot, J. P. Collet, R. Choussat, and D. Thomas, “Fibrinogen as a risk factor for coronary heart disease,” European Heart Journal, vol. 19, pp. H11–H17, 1998. View at Google Scholar · View at Scopus
  35. T. W. Jax, A. J. Peters, G. Plehn, and F.-C. Schoebel, “Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes—a two year follow-up of 243 patients,” Cardiovascular Diabetology, vol. 8, article 48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Handa, S. Kono, K. Saku et al., “Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis,” Atherosclerosis, vol. 77, no. 2-3, pp. 209–213, 1989. View at Google Scholar · View at Scopus
  37. I. Bolibar, J. Kienast, S. G. Thompson, R. Matthias, H. Niessner, and C. Fechtrup, “Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease,” American Heart Journal, vol. 125, no. 6, pp. 1601–1605, 1993. View at Publisher · View at Google Scholar · View at Scopus
  38. X. L. Wang, J. Wang, R. M. McCredie, and D. E. L. Wilcken, “Polymorphisms of factor V, factor VII, and fibrinogen genes: relevance to severity of coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 2, pp. 246–251, 1997. View at Google Scholar · View at Scopus
  39. M. Tataru, H. Schulte, A. Von Eckardstein, J. Heinrich, G. Assmann, and E. Koehler, “Plasma fibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction,” Coronary Artery Disease, vol. 12, no. 3, pp. 157–165, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Pacilli, S. De Cosmo, V. Trischitta, and S. Bacci, “Role of relationship between HbA1c, fibrinogen and HDL-cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus,” Atherosclerosis, vol. 228, no. 1, pp. 247–248, 2013. View at Google Scholar
  41. R. Guardado-Mendoza, L. Jimenez-Ceja, M. F. Pacheco-Carrasco et al., “Fibrinogen is associated with silent myocardial ischaemia in type 2 diabetes mellitus,” Acta Cardiologica, vol. 64, no. 4, pp. 523–530, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Papageorgiou, D. Tousoulis, G. Siasos, and C. Stefanadis, “Is fibrinogen a marker of inflammation in coronary artery disease?” Hellenic Journal of Cardiology, vol. 51, no. 1, pp. 1–9, 2010. View at Google Scholar · View at Scopus